Your Global Partner for Anti-Infective Drug Development
Eurofins Medinet Anti-Infective Services offers complete laboratory and consultative support to the pharmaceutical, biotechnology, and government sectors through all phases of anti-infective drug development and commercialization. We are committed to providing you with accurate and timely results, knowledgeable and relevant scientific advice, and outstanding customer service. With over 15 years of experience in delivering microbiology testing and consultative services, our expert staff uses cutting-edge technology and adheres to the strictest national and international quality standards. As a member of the Eurofins laboratory group, a worldwide leader in bioanalytical services, we are backed by a global network of over 150 laboratories in 28 countries.

Central Laboratory Microbiology to Support Clinical Trials
Eurofins Medinet Anti-Infective Services combines scientific and laboratory expertise in bacteriology and mycology with a full range of global central laboratory services. We are equipped to perform organism identification, characterization, and antimicrobial susceptibility testing using conventional, automated, and molecular methods.

We also offer complete central laboratory services, including project and data management, logistics and courier management services, quality assurance, regulatory compliance, and global operating standards. This comprehensive array of capabilities allows us to provide you with flexible and cost-effective services and assure the production of accurate, reliable, and timely results.

Specialty Microbiology
In addition to the microbiology capabilities to support clinical trials and surveillance, Eurofins Medinet Anti-Infective Services offers the full spectrum of laboratory based tests required by the US FDA to characterize new drugs as part of the New Drug Application (NDA).

Such testing includes:
- Molecular Characterization (PCR, Sequencing)
- Molecular Typing (PFGE, Ribotyping)
- Lead Compound Screening
- Resistance Development
- Bactericidal Activities (Timekill)
- Synergy/Antagonism
- Post-Antibiotic Effect (PAE)
- Development of Disk Diffusion and MIC Methodologies
- Quality Control Range Development
- Interpretive Breakpoint Determinations
Antimicrobial Surveillance
Eurofins Medinet Anti-Infective Services offers global surveillance service and houses one of the world’s largest repositories of current, characterized and clinically relevant bacterial pathogens. In addition to using our vast organism repository to profile antimicrobial agents in development, we have designed and managed many of the largest and longest running national and international surveillance projects to prospectively monitor the ongoing in vitro effectiveness of several leading antimicrobial agents.

Eurofins Medinet Anti-Infective Services also offers The Surveillance Network (TSN), the only electronic surveillance database that collects strain-specific, qualitative, and quantitative antimicrobial resistance test results daily from clinical laboratories across the USA. TSN allows our clients to access a robust and reliable source of antimicrobial susceptibility data and evaluate resistance patterns in real-time to answer key questions about antimicrobial development and market potential.

Scientific Consultative Services
Eurofins Medinet Anti-Infective Services draws on the extensive scientific, drug development, and regulatory experience of our expert staff to bring value to every stage of your drug’s development.

Our team is made up of recognized authorities in infectious diseases, anti-infective research, and antimicrobial resistance with broad industry experience. Eurofins Medinet scientists have prepared numerous NDA submissions documents, presented data to the US FDA, CLSI, EUCAST, and EMEA, and produced hundreds of scientific presentations and publications.

“We are as proud of our accomplishments as we are of our commitment to quality, integrity, teamwork, and customer service. The success of your Anti-Infective drug development program is our top priority.”

-Dr. Dan Sahm